Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: Distribution along margin of fibrotic lesions

A. Tamura, S. Kusachi, I. Nogami, A. Yamanishi, Y. Kajikawa, S. Hirohata, T. Tsuji

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective - To examine the hypothesis that tenascin, an extracellular matrix glycoprotein, contributes to fibrotic changes in dilated cardiomyopathy. Methods - The localisation of tenascin in biopsy specimens of the hearts obtained from eight patients with dilated cardiomyopathy was examined using staining by the avidin-biotin-peroxidase complex method Results - (1) Perimysium and endomysium. Although positive staining for tenascin was observed in the enlarged perimysium and endomysium in all patients, moderately intense staining was characteristically observed near the replacement fibrotic lesions. In the narrow perimysium and endomysium of the myocardium not containing replacement fibrotic lesions, tenascin was not present, as in the control specimens. (2) Replacement fibrotic lesions. Non-homogeneous positive staining for tenascin was detected in all replacement fibrotic lesions examined. Intense tenascin deposition was observed in the peripheral portion of the replacement fibrotic lesions. The tenascin staining observed in the small replacement fibrotic lesions was more intense than that in the large lesions. Conclusions - Tenascin contributes to the development of the fibrotic changes seen in the dilated cardiomyopathic heart. Its characteristic location, specifically the distribution along the margin of the fibrosis, suggests that fibrotic change is a continuous process in hearts with dilated cardiomyopathy.

Original languageEnglish
Pages (from-to)291-294
Number of pages4
JournalHeart
Volume75
Issue number3
Publication statusPublished - 1996

Fingerprint

Tenascin
Dilated Cardiomyopathy
Biopsy
Staining and Labeling
Avidin
Biotin
Peroxidase
Extracellular Matrix
Myocardium
Glycoproteins
Fibrosis

Keywords

  • Cardiac fibrosis
  • Extracellular matrix components
  • Glycoprotein
  • Polyclonal antibody

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy : Distribution along margin of fibrotic lesions. / Tamura, A.; Kusachi, S.; Nogami, I.; Yamanishi, A.; Kajikawa, Y.; Hirohata, S.; Tsuji, T.

In: Heart, Vol. 75, No. 3, 1996, p. 291-294.

Research output: Contribution to journalArticle

Tamura, A, Kusachi, S, Nogami, I, Yamanishi, A, Kajikawa, Y, Hirohata, S & Tsuji, T 1996, 'Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: Distribution along margin of fibrotic lesions', Heart, vol. 75, no. 3, pp. 291-294.
Tamura, A. ; Kusachi, S. ; Nogami, I. ; Yamanishi, A. ; Kajikawa, Y. ; Hirohata, S. ; Tsuji, T. / Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy : Distribution along margin of fibrotic lesions. In: Heart. 1996 ; Vol. 75, No. 3. pp. 291-294.
@article{f23e94c87cdd48b6bcdecf19d19f396b,
title = "Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: Distribution along margin of fibrotic lesions",
abstract = "Objective - To examine the hypothesis that tenascin, an extracellular matrix glycoprotein, contributes to fibrotic changes in dilated cardiomyopathy. Methods - The localisation of tenascin in biopsy specimens of the hearts obtained from eight patients with dilated cardiomyopathy was examined using staining by the avidin-biotin-peroxidase complex method Results - (1) Perimysium and endomysium. Although positive staining for tenascin was observed in the enlarged perimysium and endomysium in all patients, moderately intense staining was characteristically observed near the replacement fibrotic lesions. In the narrow perimysium and endomysium of the myocardium not containing replacement fibrotic lesions, tenascin was not present, as in the control specimens. (2) Replacement fibrotic lesions. Non-homogeneous positive staining for tenascin was detected in all replacement fibrotic lesions examined. Intense tenascin deposition was observed in the peripheral portion of the replacement fibrotic lesions. The tenascin staining observed in the small replacement fibrotic lesions was more intense than that in the large lesions. Conclusions - Tenascin contributes to the development of the fibrotic changes seen in the dilated cardiomyopathic heart. Its characteristic location, specifically the distribution along the margin of the fibrosis, suggests that fibrotic change is a continuous process in hearts with dilated cardiomyopathy.",
keywords = "Cardiac fibrosis, Extracellular matrix components, Glycoprotein, Polyclonal antibody",
author = "A. Tamura and S. Kusachi and I. Nogami and A. Yamanishi and Y. Kajikawa and S. Hirohata and T. Tsuji",
year = "1996",
language = "English",
volume = "75",
pages = "291--294",
journal = "Heart",
issn = "1355-6037",
publisher = "BMJ Publishing Group",
number = "3",

}

TY - JOUR

T1 - Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy

T2 - Distribution along margin of fibrotic lesions

AU - Tamura, A.

AU - Kusachi, S.

AU - Nogami, I.

AU - Yamanishi, A.

AU - Kajikawa, Y.

AU - Hirohata, S.

AU - Tsuji, T.

PY - 1996

Y1 - 1996

N2 - Objective - To examine the hypothesis that tenascin, an extracellular matrix glycoprotein, contributes to fibrotic changes in dilated cardiomyopathy. Methods - The localisation of tenascin in biopsy specimens of the hearts obtained from eight patients with dilated cardiomyopathy was examined using staining by the avidin-biotin-peroxidase complex method Results - (1) Perimysium and endomysium. Although positive staining for tenascin was observed in the enlarged perimysium and endomysium in all patients, moderately intense staining was characteristically observed near the replacement fibrotic lesions. In the narrow perimysium and endomysium of the myocardium not containing replacement fibrotic lesions, tenascin was not present, as in the control specimens. (2) Replacement fibrotic lesions. Non-homogeneous positive staining for tenascin was detected in all replacement fibrotic lesions examined. Intense tenascin deposition was observed in the peripheral portion of the replacement fibrotic lesions. The tenascin staining observed in the small replacement fibrotic lesions was more intense than that in the large lesions. Conclusions - Tenascin contributes to the development of the fibrotic changes seen in the dilated cardiomyopathic heart. Its characteristic location, specifically the distribution along the margin of the fibrosis, suggests that fibrotic change is a continuous process in hearts with dilated cardiomyopathy.

AB - Objective - To examine the hypothesis that tenascin, an extracellular matrix glycoprotein, contributes to fibrotic changes in dilated cardiomyopathy. Methods - The localisation of tenascin in biopsy specimens of the hearts obtained from eight patients with dilated cardiomyopathy was examined using staining by the avidin-biotin-peroxidase complex method Results - (1) Perimysium and endomysium. Although positive staining for tenascin was observed in the enlarged perimysium and endomysium in all patients, moderately intense staining was characteristically observed near the replacement fibrotic lesions. In the narrow perimysium and endomysium of the myocardium not containing replacement fibrotic lesions, tenascin was not present, as in the control specimens. (2) Replacement fibrotic lesions. Non-homogeneous positive staining for tenascin was detected in all replacement fibrotic lesions examined. Intense tenascin deposition was observed in the peripheral portion of the replacement fibrotic lesions. The tenascin staining observed in the small replacement fibrotic lesions was more intense than that in the large lesions. Conclusions - Tenascin contributes to the development of the fibrotic changes seen in the dilated cardiomyopathic heart. Its characteristic location, specifically the distribution along the margin of the fibrosis, suggests that fibrotic change is a continuous process in hearts with dilated cardiomyopathy.

KW - Cardiac fibrosis

KW - Extracellular matrix components

KW - Glycoprotein

KW - Polyclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=0029928553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029928553&partnerID=8YFLogxK

M3 - Article

C2 - 8800995

AN - SCOPUS:0029928553

VL - 75

SP - 291

EP - 294

JO - Heart

JF - Heart

SN - 1355-6037

IS - 3

ER -